BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Research Notes

Keros Therapeutics: A Quarter That Earned Its Keep, and the Longer Bet Behind It

Moe Alsumidaie by Moe Alsumidaie
November 18, 2026
in Research Notes
0
75
SHARES
1.3k
VIEWS
Share on XShare on LinkedInShare on Facebook

Eighteen months ago, Keros cut nearly half its staff and buried its most advanced drug. Today, the same company is posting net income, sitting on a cash pile larger than its entire market value, and running three clinical programs at once. Those two facts should not coexist, and the gap between them is the story.

The short version

The math, meaning what the filed numbers actually show, is a company that turned profitable in Q3 2026 on milestone payments from partner Takeda, holds more cash than its stock market value implies, and has enough runway to reach its next major data readout without raising money. The mood, meaning what the market is currently pricing in, is closer to a company still in freefall: the stock sits well below its 52-week high. Those two readings cannot both be right, and the open question is whether the milestone-driven income is a one-time event or the first installment of something that compounds.

How it got here

Keros spent its early years as a pure research bet, burning cash on a biology platform built around proteins that regulate muscle and blood-cell growth. The company earned almost nothing in revenue for several years running, losing a meaningful amount per share each year, according to our data computed from SEC filings. Then, in January 2025, its lead drug cibotercept (KER-012) started causing fluid buildup around patients’ hearts in a Phase 2 pulmonary hypertension trial. Dosing stopped. By May 2025, Keros discontinued the program entirely and cut nearly half its workforce. The stock collapsed.

What survived the wreckage was elritercept, a compound aimed at blood disorders, and a younger asset called rinvatercept targeting muscle disease. The company had quietly licensed elritercept to Takeda, and that deal is now paying out in milestones as the drug advances through trials.

BullScope TerminalKROS was the article. The engine is the product.Same yardsticks, any ticker: filed financials in, math-vs-mood out. Nothing here is advice; it is the evidence, organized.Run another company →

What the quarter actually shows

The 10-Q filed November 5, 2026, for the quarter ended September 30, covers a company in a different posture than a year ago. Keros recorded $40 million in license revenue during Q3, both payments tied to Takeda hitting development milestones for elritercept: the first patients dosed in Phase 3 trials for two blood disorders, myelodysplastic syndromes and myelofibrosis. That revenue flipped the quarter to a $14.2 million net profit, compared with a loss in the same quarter of 2025.

The honest weight of one quarter is not much. Milestone revenue is lumpy by design: a partner hits a clinical gate, a payment arrives, and then the calendar goes quiet until the next gate. The underlying quarterly cost structure did not change. A reader looking at this quarter should see a signal, not a trend.

The cash question

What does compound is the cash position. Keros reported $259.5 million in cash as of September 30, per the Q3 filing, and then received an additional milestone from Takeda in November 2026, as reported by BioSpace. The company says it funds operations into the second half of 2028, a projection that predates the November payment, meaning the actual runway is longer still.

For context: the stock’s last tape price puts the whole company’s market value at roughly the same order of magnitude as the cash it already holds. A business where the safe in the lobby is worth nearly as much as the building is a structure that valuation frameworks often flag for closer examination, though the discount can persist as long as pipeline risk remains unresolved.

What is moving in the clinics

Rinvatercept dosed its first DMD patient in late September 2026, opening a Phase 2 basket trial in Duchenne muscular dystrophy, a disease that progressively destroys muscle in young patients. Initial safety data is expected in the first half of 2027. Keros also plans to engage regulators on a separate rinvatercept trial in ALS before year-end, aiming to start that study in 2027. And in October 2026, the company nominated KER-206, a bone-remodeling compound, for further investigation, presenting early nonclinical data at a major research conference.

HC Wainwright analyst A. Maldonado, writing in early November 2026, raised the firm’s full-year earnings estimate; the firm’s published rating and valuation reference are on record at MarketBeat and reflect that analyst’s independent methodology, not BullScope’s view. TipRanks’ AI tool Spark issued a Neutral shortly after, citing volatile financials while acknowledging the pipeline progress. Those two views bracket the tension neatly: the near-term numbers are lumpy, and the long-term story depends on clinical outcomes that will not be known for years.

Reading the numbers

  • $40M Q3 license revenue (filed in the Q3 2026 10-Q): two $20M milestones from Takeda, each triggered by dosing the first patient in a Phase 3 trial and both recognized as Q3 revenue, though the second payment was physically received in November 2026. Think of it as a landlord collecting a deposit when a tenant signs: real money, but it does not recur until the next lease event. Without it, the quarter would have been a loss.
  • $259.5M cash (same filing, as of September 30, 2026): at roughly $27M in quarterly operating costs, this is about nine quarters of runway before the November milestone is added. A household analogy: a family with $260,000 in savings and $27,000 in annual expenses can keep the lights on for nearly a decade without earning another dollar, though they would prefer not to.
  • $11.31 stock price vs. cash (tape price as of November 10, 2026, sourced from Nasdaq): the stock trades at a price-to-sales ratio of 0.8 (calculated from the Q3 2026 10-Q revenue figure and the tape price noted above); for reference, the decade median per our published valuation methodology is 74.5, though that figure reflects years when revenue was near zero and milestone-inflated figures make direct comparison unreliable, IF revenue were to normalize to a recurring base and IF the multiple were to revert toward a more typical range, the arithmetic would look materially different, but neither condition is established. The low ratio here is partly a math artifact of milestone-inflated FY2025 revenue, but it also signals that the market is not paying much for the pipeline beyond what the cash already represents.

Sources

  • Keros 10-Q, quarter ended September 30, 2026 (SEC EDGAR)
  • TradingView: Keros Q3 2026 net income and pipeline progress
  • BioSpace: Keros Q3 2026 business highlights and financial results
  • MedPath: Keros discontinues PAH program
  • ClinicalTrials.gov: TROPOS trial (NCT05975905)
  • MarketBeat: HC Wainwright FY2026 EPS estimate for KROS
  • TradingView: Keros Q3 2026 revenue and EPS summary
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read KROS’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

LifeVantage: A $58 Million Buyback Program and a Quarter That Lost Money

by Moe Alsumidaie
November 20, 2026
0

LifeVantage spent most of the last decade building its reputation on a single idea: that a supplement called Protandim could slow the cellular wear-and-tear that comes with aging....

Read moreDetails

AnaptysBio: The Royalty Company That Used to Be a Drug Company

by Moe Alsumidaie
November 19, 2026
0

For most of its life, AnaptysBio was a bet on science. It discovered drug candidates, ran trials, and hoped one would survive long enough to reach patients. Then,...

Read moreDetails

Vafseo Is Growing. Auryxia Is Collapsing. Both Are True at Once.

by Moe Alsumidaie
November 19, 2026
0

Four years ago, Akebia Therapeutics was a company the FDA had just rejected, laying off nearly half its staff and watching its lead partner walk away. Today, that...

Read moreDetails

Vaxart: Government Revenue Falls 85%, and the Clock Starts Ticking

by Moe Alsumidaie
November 19, 2026
0

A year ago, Vaxart looked like a company with a government backstop. BARDA, the federal agency that funds pandemic preparedness, had committed hundreds of millions of dollars to...

Read moreDetails

Schrödinger: The Cost Machine That Learned to Cost Less

by Moe Alsumidaie
November 17, 2026
0

Schrödinger spent three decades building physics simulations so precise that major pharmaceutical companies use them to design drugs before synthesizing a single molecule. It went public in February...

Read moreDetails
Next Post

Vaxart: Government Revenue Falls 85%, and the Clock Starts Ticking

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Ultragenyx: A Stock at Its Cheapest in a Decade, and the One Number That Explains Why

October 5, 2026

Evidence Sheet: Caribou Biosciences (CRBU)

November 6, 2026

Rigel Pharmaceuticals: A $70 Million Bet Sitting Next to $95 Million in Cash

October 30, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.